Literature DB >> 27489360

Amplification of TLK2 Induces Genomic Instability via Impairing the G2-M Checkpoint.

Jin-Ah Kim1, Meenakshi Anurag1, Jamunarani Veeraraghavan1, Rachel Schiff1, Kaiyi Li2, Xiao-Song Wang3.   

Abstract

Managing aggressive breast cancers with enhanced chromosomal instability (CIN) is a significant challenge in clinics. Previously, we described that a cell cycle-associated kinase called Tousled-like kinase 2 (TLK2) is frequently deregulated by genomic amplifications in aggressive estrogen receptor-positive (ER+) breast cancers. In this study, it was discovered that TLK2 amplification and overexpression mechanistically impair Chk1/2-induced DNA damage checkpoint signaling, leading to a G2-M checkpoint defect, delayed DNA repair process, and increased CIN. In addition, TLK2 overexpression modestly sensitizes breast cancer cells to DNA-damaging agents, such as irradiation or doxorubicin. To our knowledge, this is the first report linking TLK2 function to CIN, in contrast to the function of its paralog TLK1 as a guardian of genome stability. This finding yields new insight into the deregulated DNA damage pathway and increased genomic instability in aggressive ER+ breast cancers. IMPLICATIONS: Targeting TLK2 presents an attractive therapeutic strategy for the TLK2-amplified breast cancers that possess enhanced genomic instability and aggressiveness. Mol Cancer Res; 14(10); 920-7. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27489360      PMCID: PMC5065758          DOI: 10.1158/1541-7786.MCR-16-0161

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  27 in total

Review 1.  Mechanisms and regulation of the degradation of cyclin B.

Authors:  A Hershko
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  Mammalian homologues of the plant Tousled gene code for cell-cycle-regulated kinases with maximal activities linked to ongoing DNA replication.

Authors:  H H Silljé; K Takahashi; K Tanaka; G Van Houwe; E A Nigg
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

3.  microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Authors:  Giannicola Genovese; Ayla Ergun; Sachet A Shukla; Benito Campos; Jason Hanna; Papia Ghosh; Steven N Quayle; Kunal Rai; Simona Colla; Haoqiang Ying; Chang-Jiun Wu; Sharmistha Sarkar; Yonghong Xiao; Jianhua Zhang; Hailei Zhang; Lawrence Kwong; Katherine Dunn; Wolf Ruprecht Wiedemeyer; Cameron Brennan; Hongwu Zheng; David L Rimm; James J Collins; Lynda Chin
Journal:  Cancer Discov       Date:  2012-06-29       Impact factor: 39.397

4.  Patterns and incidence of chromosomal instability and their prognostic relevance in breast cancer subtypes.

Authors:  Marcel Smid; Marlous Hoes; Anieta M Sieuwerts; Stefan Sleijfer; Yi Zhang; Yixin Wang; John A Foekens; John W M Martens
Journal:  Breast Cancer Res Treat       Date:  2010-07-15       Impact factor: 4.872

Review 5.  The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance.

Authors:  Peter Bouwman; Jos Jonkers
Journal:  Nat Rev Cancer       Date:  2012-09       Impact factor: 60.716

6.  Supervised risk predictor of breast cancer based on intrinsic subtypes.

Authors:  Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard
Journal:  J Clin Oncol       Date:  2009-02-09       Impact factor: 44.544

7.  Tousled homolog, TLK1, binds and phosphorylates Rad9; TLK1 acts as a molecular chaperone in DNA repair.

Authors:  Gulshan Sunavala-Dossabhoy; Arrigo De Benedetti
Journal:  DNA Repair (Amst)       Date:  2008-11-05

Review 8.  Aurora kinase inhibitors: progress towards the clinic.

Authors:  Madhu Kollareddy; Daniella Zheleva; Petr Dzubak; Pathik Subhashchandra Brahmkshatriya; Martin Lepsik; Marian Hajduch
Journal:  Invest New Drugs       Date:  2012-02-18       Impact factor: 3.850

9.  BRIT1/MCPH1 is essential for mitotic and meiotic recombination DNA repair and maintaining genomic stability in mice.

Authors:  Yulong Liang; Hong Gao; Shiaw-Yih Lin; Guang Peng; Xingxu Huang; Pumin Zhang; John A Goss; Francis C Brunicardi; Asha S Multani; Sandy Chang; Kaiyi Li
Journal:  PLoS Genet       Date:  2010-01-22       Impact factor: 5.917

Review 10.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

View more
  11 in total

1.  Chemoproteomic Discovery of a Ritanserin-Targeted Kinase Network Mediating Apoptotic Cell Death of Lung Tumor Cells.

Authors:  Sean T Campbell; Caroline E Franks; Adam L Borne; Myungsun Shin; Liuzhi Zhang; Ku-Lung Hsu
Journal:  Mol Pharmacol       Date:  2018-08-29       Impact factor: 4.436

2.  Differential requirements for Tousled-like kinases 1 and 2 in mammalian development.

Authors:  Sandra Segura-Bayona; Philip A Knobel; Helena González-Burón; Sameh A Youssef; Aida Peña-Blanco; Étienne Coyaud; Teresa López-Rovira; Katrin Rein; Lluís Palenzuela; Julien Colombelli; Stephen Forrow; Brian Raught; Anja Groth; Alain de Bruin; Travis H Stracker
Journal:  Cell Death Differ       Date:  2017-07-14       Impact factor: 15.828

Review 3.  Pioneering insights of extrachromosomal DNA (ecDNA) generation, action and its implications for cancer therapy.

Authors:  Zesheng Li; Bo Wang; Hao Liang; Lei Han
Journal:  Int J Biol Sci       Date:  2022-06-13       Impact factor: 10.750

4.  Molecular basis of Tousled-Like Kinase 2 activation.

Authors:  Gulnahar B Mortuza; Dario Hermida; Anna-Kathrine Pedersen; Sandra Segura-Bayona; Blanca López-Méndez; Pilar Redondo; Patrick Rüther; Irina Pozdnyakova; Ana M Garrote; Inés G Muñoz; Marina Villamor-Payà; Cristina Jauset; Jesper V Olsen; Travis H Stracker; Guillermo Montoya
Journal:  Nat Commun       Date:  2018-06-28       Impact factor: 14.919

5.  The circadian E3 ligase complex SCFFBXL3+CRY targets TLK2.

Authors:  Stephanie Papp Correia; Alanna B Chan; Megan Vaughan; Norjin Zolboot; Valerie Perea; Anne-Laure Huber; Anna Kriebs; James J Moresco; John R Yates; Katja A Lamia
Journal:  Sci Rep       Date:  2019-01-17       Impact factor: 4.379

6.  Inactive Tlk associating with Tak1 increases p38 MAPK activity to prolong the G2 phase.

Authors:  Gwo-Jen Liaw; Chuen-Sheue Chiang
Journal:  Sci Rep       Date:  2019-02-13       Impact factor: 4.379

7.  Retrospective clinical trial experimentally validates glioblastoma genome-wide pattern of DNA copy-number alterations predictor of survival.

Authors:  Sri Priya Ponnapalli; Matthew W Bradley; Karen Devine; Jay Bowen; Sara E Coppens; Kristen M Leraas; Brett A Milash; Fuqiang Li; Huijuan Luo; Shi Qiu; Kui Wu; Huanming Yang; Carl T Wittwer; Cheryl A Palmer; Randy L Jensen; Julie M Gastier-Foster; Heidi A Hanson; Jill S Barnholtz-Sloan; Orly Alter
Journal:  APL Bioeng       Date:  2020-05-15

8.  JMJD1B, a novel player in histone H3 and H4 processing to ensure genome stability.

Authors:  Francisco Saavedra; Zachary A Gurard-Levin; Camila Rojas-Villalobos; Isabelle Vassias; Raquel Quatrini; Geneviève Almouzni; Alejandra Loyola
Journal:  Epigenetics Chromatin       Date:  2020-02-18       Impact factor: 4.954

9.  Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity.

Authors:  Xian Wang; Ying Tan; Xixi Cao; Jin Ah Kim; Tianmeng Chen; Yiheng Hu; Matthew Wexler; Xiaosong Wang
Journal:  Oncotarget       Date:  2018-07-10

Review 10.  Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.

Authors:  Xiang Gu; Jie Yu; Peiwei Chai; Shengfang Ge; Xianqun Fan
Journal:  J Exp Clin Cancer Res       Date:  2020-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.